HUMA Valuation

Humacyte Inc

Add to Watchlist

Advanced Chart

2.530

-0.14(-5.243%)1D

Overview
Forecast
Valuation
Earnings

HUMA Relative Valuation

HUMA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HUMA is overvalued; if below, it's undervalued.

Historical Valuation

Humacyte Inc (HUMA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 32.98 is considered Undervalued compared with the five-year average of -6.04. The fair price of Humacyte Inc (HUMA) is between 2.60 to 7.32 according to relative valuation methord. Compared to the current price of 2.53 USD , Humacyte Inc is Undervalued By 2.82%.

Relative Value

Fair Zone

2.60-7.32

Current Price：2.53

2.82%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

11.49

P/B

Median3y

2.62

Median5y

2.90

-23.80

FCF Yield

Median3y

-21.71

Median5y

-19.51

Competitors Valuation Multiple

The average P/S ratio for HUMA's competitors is 24.01, providing a benchmark for relative valuation. Humacyte Inc Corp (HUMA) exhibits a P/S ratio of 32.98, which is 37.36% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap